Calamos Advisors LLC Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Calamos Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 252,818 shares of the biopharmaceutical company’s stock after selling 4,767 shares during the quarter. Calamos Advisors LLC’s holdings in Gilead Sciences were worth $20,481,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd increased its position in shares of Gilead Sciences by 7.0% in the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 121 shares during the last quarter. Nilsine Partners LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after buying an additional 127 shares during the period. Etesian Wealth Advisors Inc. boosted its holdings in shares of Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares during the period. Financial Counselors Inc. boosted its holdings in shares of Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 128 shares during the period. Finally, Revolve Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 130 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded up $0.27 during midday trading on Friday, reaching $66.43. The company’s stock had a trading volume of 906,160 shares, compared to its average volume of 7,221,661. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The company has a 50 day moving average price of $72.10 and a 200 day moving average price of $76.58. Gilead Sciences, Inc. has a one year low of $65.90 and a one year high of $87.86. The company has a market cap of $82.71 billion, a price-to-earnings ratio of 14.70, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the previous year, the firm earned $1.67 earnings per share. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a dividend of $0.77 per share. The ex-dividend date was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.64%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s payout ratio is currently 68.44%.

Analysts Set New Price Targets

GILD has been the subject of several research reports. Mizuho decreased their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Cantor Fitzgerald reduced their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Barclays reduced their target price on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, February 12th. Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Finally, Oppenheimer reduced their target price on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Hold” and an average price target of $84.71.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.